ABBV-154 / AbbVie  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ABBV-154 / AbbVie
AIM-RA, NCT04888585 / 2020-005303-39: Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Terminated
2
473
Europe, Canada, Japan, US, RoW
ABBV-154, Placebo
AbbVie
Rheumatoid Arthritis (RA)
08/22
08/23
2021-002869-18: This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD) Este estudio es para evaluar la seguridad y eficacia de ABBV-154 en pacientes con Enfermedad de Crohn Activa de moderada a grave

Not yet recruiting
2
265
Europe, RoW
ABBV-154, ABBV-154, Powder for solution for infusion, Solution for injection in pre-filled syringe
AbbVie Deutschland GmbH & Co. KG, ABBVIE DEUTSCHLAND GMBH & CO. KG, AbbVie Inc., Abbvie Inc.
Subjects with moderately to severely active Crohn's disease Pacientes con Enfermedad de Crohn activada de moderada a grave, Crohn's disease Enfermedad de Crohn, Diseases [C] - Immune System Diseases [C20]
 
 
AIM-CD, NCT05068284: A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

Calendar Jan 2024 - Dec 2024: Data from AIM-CD trial for Crohn’s disease
Terminated
2
176
Europe, Canada, Japan, US, RoW
ABBV-154, Placebo
AbbVie
Crohn's Disease
07/23
07/23
AIM-PMR, NCT04972968 / 2021-000648-23: A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154

Terminated
2
181
Europe, Canada, Japan, US, RoW
ABBV-154, Placebo, Glucocorticoid
AbbVie
Polymyalgia Rheumatica
07/23
07/23

Download Options